Lotiglipron

Lotiglipron
Identifiers
IUPAC name
  • 2-{[4-[(2S)-2-(5-chloropyridin-2-yl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl]methyl}-3-{[(2S)-oxetan-2-yl]methyl}benzimidazole-5-carboxylic acid
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC31H31ClN4O5
Molar mass575.06 g·mol−1
3D model (JSmol)
SMILES
  • C[C@@]1(OC2=CC=CC(=C2O1)C3CCN(CC3)CC4=NC5=C(N4C[C@@H]6CCO6)C=C(C=C5)C(=O)O)C7=NC=C(C=C7)Cl
InChI
  • InChI=1S/C31H31ClN4O5/c1-31(27-8-6-21(32)16-33-27)40-26-4-2-3-23(29(26)41-31)19-9-12-35(13-10-19)18-28-34-24-7-5-20(30(37)38)15-25(24)36(28)17-22-11-14-39-22/h2-8,15-16,19,22H,9-14,17-18H2,1H3,(H,37,38)/t22-,31-/m0/s1
  • Key:SVPYZAJTWFQTSM-UGDMGKLASA-N

Lotiglipron is a non-peptide glucagon-like peptide-1 receptor agonist developed as a weight loss drug by Pfizer.[1] It was withdrawn from development after early stage clinical trials showed elevated liver enzymes which could indicate potential for liver toxicity.[2]

See also

References

  1. ↑ US 10676465, Aspnes GE, et al., "GLP-1 receptor agonists and uses thereof", issued 9 June 2020, assigned to Pfizer Inc
  2. ↑ Griffin M (26 June 2023). "Pfizer Shares Drop After It Halts Development of Obesity Drug Due to Safety Concerns". Time.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.